Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Sebastian, Jones, Robin L., Blay, Jean-Yves, Gelderblom, Hans, George, Suzanne, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Su, Ying, Meade, Julie, Wang, Tao, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746771/
https://www.ncbi.nlm.nih.gov/pubmed/35947817
http://dx.doi.org/10.1200/JCO.22.00294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746771/
https://www.ncbi.nlm.nih.gov/pubmed/35947817
http://dx.doi.org/10.1200/JCO.22.00294

Ejemplares similares